Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine micro-reduction pilot for opioid dependence tapering
ACTRN12614001239651Phase 4Terminated
- Sponsor
- Assoc Prof Robert Ali
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of buprenorphine and buprenorphine + naloxone in opioid use disorder (OUD), sponsored by Assoc Prof Robert Ali. Primary endpoints: Sensitivity of withdrawal measures to buprenorphine dose reduction, Clinical Opiate Withdrawal Scale and 3 more. Started Oct 2015; status: terminated.
02
Drugs
buprenorphinebuprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on ACTRN12614001239651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001239651.